Abstracts Archive - Page 1584 of 2425 - ACR Meeting Abstracts

Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 2506 • 2016 ACR/ARHP Annual Meeting
Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy
Mihir D. Wechalekar^1,2, Susan Lester³, Sunil Nagpal⁴, Jessica Peters⁵, Anuk Das⁶, Pravin Hissaria^7,8, Tania Crotti⁹, Llew Spargo¹⁰, Jennifer G Walker^1,2,10, Malcolm D. Smith¹ and Susanna M Proudman^9,10, ¹Flinders University, Adelaide, Australia, ²Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, ³Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁴Immunology, Janssen Research & Development, Spring House, PA, ⁵Janssen Research & Development, Spring House, PA, ⁶Janssen R&D, Berwyn, PA, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Immunology, SA Pathology, Adelaide, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: There are limited data regarding the role of and response to treatment, of bone biomarkers in early rheumatoid arthritis (RA) treated with conventional DMARDs.…
Abstract Number: 2507 • 2016 ACR/ARHP Annual Meeting
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) has been recommended for the first line therapy of rheumatoid arthritis (RA), either alone or in combination with other DMARDs such as…
Abstract Number: 2508 • 2016 ACR/ARHP Annual Meeting
Significant Improvement of Rheumatoid Arthritis (RA) Outcome with Repeat Application of Disease Management (SSDM) Mobiles Tools: A Cohort Study of RA Patients in China
Jing Yang¹, Hongzhi Wang², Wenqiang Fan³, Hua Wei⁴, Xinwang Duan⁵, Rong Mu⁶, Yu Zhang¹, Xiafei Xin⁷, Jinmei Zou¹, Xiaofeng Li⁸, Jie Wu⁹, Xiaomei Li¹⁰, Guosheng Wang¹¹, Hong Liu¹, Fei Xiao¹², Hui Xiao¹², Yuhua Jia¹², Yuan Liu¹², Bing Wu¹² and Xiaofeng Zeng¹³, ¹Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ²The First Hospital of Jiaxing, Jiaxing, China, ³Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁴No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁵Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Ningbo First Hospital, Zhejiang, Ningbo, China, ⁸The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China, ⁹Central Hospital of XinXiang, Henan, XinXiang, China, ¹⁰Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹¹Department of rheumatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China, ¹²Gothic Internet Technology Corporation, Shanghai, China, ¹³Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-Target (T2T) strategy are critical for the treatment…
Abstract Number: 2509 • 2016 ACR/ARHP Annual Meeting
Implementation of the Treat to Target Concept in Evaluation of Rheumatoid Arthritis Patients
Devy Zisman^1,2, Shirly Oren³, T. Reitblat⁴, Merav Lidar⁵, Alexandra Balbir-Gurman⁶, Itzhak A. Rosner⁷, Joy Feld², Nimer Halabi⁸, Sameer Kassem⁸ and Ori Elkayam⁹, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁴Barzilai Medical Center, Ashkelon, Israel, ⁵Medicine F, Sheba Medical Center, Ramat Gan, Israel, ⁶B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁷Bnai Zion Medical Center, Haifa, Israel, ⁸Internal Medicine, Carmel Medical Center, Haifa, Israel, ⁹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: To assess the implementation of the treat to target (T2T) concept in rheumatoid arthritis (RA) patients. Methods: Academic rheumatology units were invited to participate…
Abstract Number: 2510 • 2016 ACR/ARHP Annual Meeting
Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases
Jesús Tornero Molina¹, Jaime Calvo², Francisco Javier Ballina-García³, María Ángeles Belmonte⁴, Francisco J. Blanco^5,6, Miguel Angel Caracuel-Ruiz⁷, Jordi Carbonell⁸, Hector Corominas⁹, Eugenio Chamizo Carmona¹⁰, C. Hidalgo-Calleja¹¹, Jose Andres Roman Ivorra¹², José Luis Marenco de la Fuente¹³, J.V. Moreno¹⁴, Santiago Muñoz Fernandez¹⁵, Joan Miquel Nolla¹⁶, Trinidad Perez Sandoval¹⁷, Raimon Sanmarti¹⁸, Pilar Trenor¹⁹, Claudia Urrego²⁰, Javier Vidal¹ and José Rosas²¹, ¹Rheumatology Unit, Hospital de Guadalajara, Guadalajara, Spain, ²Rheumatology Unit, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ³Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, ⁷Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸Rheumatology Unit, Hospital del Mar, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Rheumatology, Hospital de Mérida, Mérida, Spain, ¹¹University of Salamanca Hospital, Salamanca, Spain, ¹²Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ¹³Rheumatology, Hospital de Valme, Seville, Spain, ¹⁴Rheumatologist. Vall D’Hebron Hospital, Barcelona, Spain, ¹⁵Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ¹⁶Rheumatology, Bellvitge University Hospital, Barcelona, Spain, ¹⁷Rheumatology, Hospital de León, LEÓN, Spain, ¹⁸Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁹Rheumatology Unit, Hospital Clínico de Valencia, Valencia, Spain, ²⁰Hospital G. Segovia, Segovia, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain
Background/Purpose: To develop recommendations for the management of parenteral MTX in rheumatic diseases based on best evidence and experience. Methods: A group of 21 experts…
Abstract Number: 2511 • 2016 ACR/ARHP Annual Meeting
Longitudinal Observation of Disease Activity and Treatment of Rheumatoid Arthritis Who Developed Methotrexate-Associated Lymphoproliferative Disorders
Atsumu Osada¹, Koji Kobayashi², Yuji Yoshioka³, Haruko Ideguchi³ and Shohei Nagaoka³, ¹Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²Yokohama City University Medical Center, Yokohama, Japan, ³Yokohama Minami Kyosai Hospital, Yokohama, Japan
Background/Purpose: Methotrexate-associated lymphoproliferative disorder(MTX-LPD) is rare but one of important complications in treatment of rheumatoid arthritis (RA). There are few reports about disease activity and…
Abstract Number: 2512 • 2016 ACR/ARHP Annual Meeting
Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden
Jon T. Einarsson¹, Minna Willim¹, Sofia Ernestam², Tore Saxne¹, Pierre Geborek¹ and Meliha C. Kapetanovic¹, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Remission has become a treatment goal in rheumatoid arthritis (RA) especially after the introduction of biologic treatment in 1999. The Swedish quality registry…
Abstract Number: 2513 • 2016 ACR/ARHP Annual Meeting
Maintained Remission in Rheumatoid Arthritis over 7 Years in «Real Life Conditions» : A Monocentric Observational Study
Justine Vix¹, Elodie Loppin¹ and Elisabeth Solau-Gervais², ¹Rheumatology, University Hospital Poitiers, Poitiers, France, ²rheumatology, University Hospital Poitiers, Poitiers, France
Background/Purpose: Remission constitutes the best achievable state in patients with rheumatoid arthritis (RA). And if remission is a goal, it need to be maintained. The…
Abstract Number: 2514 • 2016 ACR/ARHP Annual Meeting
Does Combination of Conventional Synthetic Disease Modifying Antirheumatic Drug with Anti-TNF Influence the Long Term Retention Compared to Anti-TNF Monotherapy in Psoriatic Arthritis? an Analysis from Rhumadata® over 12 Years
Isabelle Ferdinand¹, Louis Bessette², Josiane Bourré-Tessier³, Boulos Haraoui⁴, Jacques Brown⁵, Frédéric Massicotte³, Jean-Pierre Pelletier³, Jean-Pierre Raynauld⁴, Marie-Anaïs Rémillard⁶, Diane Sauvageau³, Angèle Turcotte⁵, Édith Villeneuve³ and Louis Coupal³, ¹University of Montreal, Montreal, QC, Canada, ²Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁵Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁶Rhumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: In rheumatoid arthritis, it has been shown that anti-TNF therapy (TNFi) in combination with a conventional synthetic disease-modifying antirheumatic drug (csDMARD), often methotrexate (MTX),…
Abstract Number: 2515 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)
Vibeke Strand¹, Kathy Lampl², Christine Birchwood³, Jinglan Pei², Katie Tuckwell⁴, Rebecca Finch⁴, Cem Gabay⁵, Arthur Kavanaugh⁶ and Graeme Jones⁷, ¹Stanford University School of Medicine, Palo Alto, CA, ²Genentech, Inc., South San Francisco, CA, ³1 DNA Way, MS# 304, Genentech, Inc., South San Francisco, CA, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Rheumatology, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁶University of California San Diego, La Jolla, CA, ⁷Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Patient-reported outcomes (PROs) are important measures when determining response to therapy in patients with RA. Previous RCTs have shown that TCZ monotherapy is superior…
Abstract Number: 2516 • 2016 ACR/ARHP Annual Meeting
Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort
Carter Thorne¹, Mohammad Movahedi², Angela Cesta², Xiuying Li², Emmanouil Rampakakis³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous studies have shown differences in the effectiveness and survival of subcutaneous vs. oral methotrexate. Furthermore, concurrent methotrexate therapy has been shown to enhance…
Abstract Number: 2517 • 2016 ACR/ARHP Annual Meeting
Long-Term Stability of the 5-Item Compliance Questionnaire Rheumatology As a Measure of Adherence in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Mary Bell², Charles H. Goldsmith³, Imy Chiu⁴, Anna Gutlin⁴ and Sharron Sandhu⁵, ¹Division of Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Simon Fraser University, Vancouver, BC, Canada, ⁴Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for optimal monitoring…
Abstract Number: 2518 • 2016 ACR/ARHP Annual Meeting
Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time
Nicola J Gullick¹, Fowzia Ibrahim², Aneela Mian¹, Alexandra Vincent³, Gabriel Panayi¹, Brian Tom⁴, David L. Scott¹ and Bruce Kirkham³, ¹Rheumatology, King's College London, London, United Kingdom, ²Academic Rheumatology Dept, King's College London, London, United Kingdom, ³Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom
Background/Purpose: There has been increasing emphasis on intensive treatment of RA but little direct evidence of the impact of such strategies on long term outcome.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].